论文部分内容阅读
daclatasvir hydrochloride(暂译名盐酸达克拉韦),中文异名为二盐酸达卡拉韦和盐酸达拉他韦,由美国百时美施贵宝公司(Bristol-Myers Squibb)研制,美国食品药品管理局(FDA)于2015年7月24日加速批准其片剂上市,商品名为Daklinza,指定与索非布韦联用,用于治疗丙型肝炎病毒基因3型慢性感染者。该文对盐酸达克拉韦非临床药理毒理学、临床药理毒理学、临床研究、适应证、剂量与用法、用药注意事项、不良反应及知识产权状态和国内外研究进展等进行介绍。
daclatasvir hydrochloride, whose Chinese names are dacraclavine dihydrochloride and daltetravir hydrochloride, developed by the Bristol-Myers Squibb company in the United States, the United States Food and Drug Administration (FDA) Accelerated the listing of its tablets on July 24, 2015 under the trade name Daklinza, designated for use with sofosbuvir for the treatment of chronic hepatitis C virus type 3 infection. This article introduces non-clinical pharmacology and toxicology of dacravir, clinical pharmacology and toxicology, clinical research, indications, dosage and usage, precautions of medication, adverse reactions, intellectual property status and research progress at home and abroad.